STAMFORD, Conn. and SYDNEY, Australia, June 7 /PRNewswire-FirstCall/ -- Novogen Limited (Nasdaq: NVGN - News; ASX: Novogen - News) has renegotiated with Marshall Edwards, Inc., (Nasdaq: MSHL - News) the timing of a US$ 8 million milestone license payment for phenoxodiol payable to Novogen Limited in December 2006, under the terms of the License Agreement for the investigational anti-cancer drug phenoxodiol.
